Phio Pharmaceuticals CEO Gerrit Dispersyn departs; Geert Cauwenbergh appointed interim CEO/CFO

Phio Pharmaceuticals Corp.

President and CEO Gerrit Dispersyn left the company effective May 5, 2022; board reduced from eight to seven.
Dispersyn to receive six months base salary severance plus six months medical/dental premium contributions.
Director Geert Cauwenbergh appointed interim principal executive and financial officer effective May 5, 2022.
Cauwenbergh previously served as Phio CEO from 2012 to 2019; will receive $7,500 monthly cash payment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Gerrit Dispersyn

President and Chief Executive Officer

PHIO · Phio Pharmaceuticals Corp.

Effective: 2022-05-05
Successor: Geert Cauwenbergh
Filed: May 10, 2022, 7:59 PM ET

On May 5, 2022, Phio Pharmaceuticals Corp. (the “Company”) announced the departure of Gerrit Dispersyn, Dr. Med. Sc., from his role as President and Chief Executive Officer of the Company, effective as of May 5, 2022

Appointed (interim)

Geert Cauwenbergh

Principal Executive and Financial Officer

PHIO · Phio Pharmaceuticals Corp.

Effective: 2022-05-05
Filed: May 10, 2022, 7:59 PM ET

On May 4, 2022, the Board appointed Geert Cauwenbergh, Dr. Med. Sc., as the Company’s interim principal executive and financial officer, effective as of May 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gerrit Dispersyn departed as President and Chief Executive Officer at Phio Pharmaceuticals Corp..

Action: departed
Role: President and Chief Executive Officer

Exact text from the filing

On May 5, 2022, Phio Pharmaceuticals Corp. (the “Company”) announced the departure of Gerrit Dispersyn, Dr. Med. Sc., from his role as President and Chief Executive Officer of the Company, effective as of May 5, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Geert Cauwenbergh was appointed as Principal Executive and Financial Officer at Phio Pharmaceuticals Corp..

Action: appointed
Role: Principal Executive and Financial Officer

Exact text from the filing

On May 4, 2022, the Board appointed Geert Cauwenbergh, Dr. Med. Sc., as the Company’s interim principal executive and financial officer, effective as of May 5, 2022.

View on SEC.gov

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-22-003391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.